Skip to Main Content

Paper Details

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Clin Cancer Res
19
2022
Author NameAffiliation
Julia A BeaverCenter for Drug Evaluation and Research
Julia A BeaverOncology Center of Excellence
  • 1 - 2

Datasets

Release 1.2